Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer

NCT00320411 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00320411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00320411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2005
Completion date
April 1, 2009
Enrollment
62 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast